Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Posted by Brenda Bartman on Jun 17th, 2026

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $88.8333.

CORT has been the subject of several research analyst reports. UBS Group set a $135.00 price objective on Corcept Therapeutics in a research note on Thursday, May 28th. Truist Financial upgraded Corcept Therapeutics to a “strong-buy” rating in a report on Monday. Zacks Research upgraded Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 4th. HC Wainwright boosted their price objective on shares of Corcept Therapeutics from $75.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. Finally, Wolfe Research upgraded shares of Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research note on Thursday, March 26th.

Get Our Latest Analysis on Corcept Therapeutics

Insider Buying and Selling at Corcept Therapeutics

In other news, CEO Joseph K. Belanoff sold 26,198 shares of the business’s stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $50.07, for a total transaction of $1,311,733.86. Following the transaction, the chief executive officer directly owned 2,918,326 shares in the company, valued at $146,120,582.82. The trade was a 0.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Joseph Douglas Lyon sold 5,000 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $65.00, for a total transaction of $325,000.00. Following the transaction, the insider owned 6,230 shares in the company, valued at approximately $404,950. This represents a 44.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 242,965 shares of company stock worth $14,802,964 over the last 90 days. 20.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Corcept Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CORT. Torren Management LLC purchased a new position in shares of Corcept Therapeutics during the 4th quarter valued at $25,000. Advisory Services Network LLC purchased a new position in shares of Corcept Therapeutics during the 3rd quarter valued at $25,000. Clearstead Advisors LLC grew its holdings in shares of Corcept Therapeutics by 163.6% during the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 193 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new position in shares of Corcept Therapeutics during the 4th quarter valued at $31,000. Finally, State of Wyoming grew its holdings in shares of Corcept Therapeutics by 29.5% during the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 186 shares in the last quarter. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

Corcept Therapeutics Stock Performance

NASDAQ CORT opened at $83.71 on Wednesday. The firm’s 50 day moving average price is $57.34 and its two-hundred day moving average price is $52.13. Corcept Therapeutics has a twelve month low of $28.66 and a twelve month high of $91.00. The stock has a market cap of $8.99 billion, a price-to-earnings ratio of 239.18 and a beta of 0.50.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last announced its earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.19). Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%. The firm had revenue of $164.90 million for the quarter, compared to analyst estimates of $185.83 million. During the same period last year, the firm earned $0.17 earnings per share. Corcept Therapeutics’s revenue for the quarter was up 4.9% compared to the same quarter last year. On average, research analysts forecast that Corcept Therapeutics will post 0.62 EPS for the current fiscal year.

Corcept Therapeutics Company Profile

(Get Free Report)

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.